Neville Rodie & Shaw Inc. Sells 3,522 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Neville Rodie & Shaw Inc. sold 3,522 shares of Edwards Lifesciences Corporation, reducing its holdings by 18.1% to 15,900 shares, which were valued at $1,244,000.
• Several institutional investors, including Farther Finance Advisors LLC and Wealth Enhancement Advisory Services LLC, increased their stakes in Edwards Lifesciences during the first quarter, indicating strong investor interest.
• Insider Larry L. Wood sold 8,950 shares, representing a 4.15% decrease in his holdings, amid a trend of insider selling with a total of 22,014 shares sold last quarter.

Neville Rodie & Shaw Inc. decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 18.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,900 shares of the medical research company's stock after selling 3,522 shares during the quarter. Neville Rodie & Shaw Inc.'s holdings in Edwards Lifesciences were worth $1,244,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Dynamic Advisor Solutions LLC boosted its holdings in shares of Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after purchasing an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after purchasing an additional 9,188 shares during the period. United Asset Strategies Inc. boosted its holdings in shares of Edwards Lifesciences by 10.4% in the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock valued at $13,450,000 after purchasing an additional 17,412 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 390.7% in the first quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock valued at $633,000 after purchasing an additional 7,013 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,014 shares of company stock valued at $1,698,844. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 0.7%

Edwards Lifesciences stock opened at $77.50 on Friday. The business has a fifty day moving average of $78.92 and a two-hundred day moving average of $75.39. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a market cap of $45.50 billion, a P/E ratio of 11.15, a P/E/G ratio of 3.76 and a beta of 1.07. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the business posted $0.70 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on EW. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Piper Sandler boosted their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, July 25th. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Truist Financial upped their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Finally, Robert W. Baird upped their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $86.26.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.